Objective: To observe the effects of Xuebijing Injection ( ) in patients with severe pneumonia, and to explore the mechanism. Methods: Eighty cases of severe pneumonia are randomly assigned to the Xuebijing treatment (forty cases) and the control group (forty cases), with the same routine therapy provided in both groups. Clinical effective rates, inflammatory factors and organ function were observed in both groups. Results: The effective rate was higher in Xuebijing group than that of the control group (80.0% vs. 67.5%, P<0.05). As compared with the control group, the LDH, 1-AG, 1-AT levels and the peak body temperature decreased markedly with the Xuebijing treatment going, and the secretion of TNF-, IL-6, IL-8 was suppressed in Xuebijing group; but no significant difference was found in leptin level.
Great progress has been achieved in antimicrobial therapeutics in recent years, yet severe pneumonia remains a major challenge in clinical treatment of pulmonary infection. The ageing society, increasing immuno-impaired hosts, diversifying pathogens as well as the rising drug resistance and other factors have lead to a rise of morbidity and mortality of severe pneumonia. Xuebijing Injection ( XBJ) is epurated from Chinese herbs, with satisfactory antiendotoxin and anti-inflammatory effects shown in clinical trials.
1,2 The present study was designed to observe the effects of Xuebijing in patients with severe pneumonia and the influences on white blood cell (WBC), lactate dehydrogenase (LDH), peak body temperature (Tmax) and acute phase reactants, and to explore the mechanism through detection of the cytokines.
METHODS

General Materials
The study evaluated the data in 80 patients with a confirmed diagnosis of severe pneumonia admitted at Respiratory Intensive Care Unit of PLA General Hospital from September 2007 to December 2009. The study was carried out with the approval from the Medical Ethics Committee of Chinese PLA General Hospital. Informed consent was obtained from all the study subjects. According to the definition formulated by American Thoracic Society in 2007, the patients with a past history of severe hepatic or renal dysfunction, rheumatic diseases, pulmonary fibrosis, tuberculosis or severe malnutrition were excluded. These 80 patients were assigned with double-blind randomized clinical study to the Xuebijing treatment group (forty cases) and the control group (forty cases).
The data were comparable between the two groups with no significant differences in gender, age, duration of illness, clinical symptoms and signs and in the Acute Physiology and Chronic Health Evaluation score as is presented in Table 1 .
Treatment
Routine anti-microbial and sputum elimination agents were given to patients of both the two groups. Xuebijing Injection produced by Tianjin Hongri Pharmaceuticals Co. Ltd. was additionally used in the Xuebijing treatment, 50 ml of Xuebijing Injection with 100 ml of normal saline administered through intravenous drip twice a day. In order to enhance the therapeutic effects, Xuebijing Injection was given after the use of antibiotics. The treatment course was 14 days for both the two groups.
Criteria for Therapeutic Effects
The therapeutic effect is excellent if the symptoms of fever, cough, expectoration and dyspnea disappear, moist and dry rales of both lungs vanish, and the chest X ray shows normal in 14 days after the treatment. The effect is moderate if the above symptoms alleviate, moist and dry rales reduce, and the chest X-ray shows partial resorption of inflammation. The treatment is ineffective if the symptoms and signs are not improved or even detoriated, and the chest X-ray reveals no resorption in 14 days. 
Indexes Observed
The peak body temperature, WBC count, neutrophils (N), and the levels of serum LDH, C-reactive protein (CRP) were measured in patients of both the groups at baseline and on the 3rd, 7th and 14th day of treatment. By means of the enzyme linked immunosorbent assay, the levels of
Statistical Analysis
The Stata software7.0 was used for statistical analysis. Parametric statistics, including student paired t-test and one-factor analysis of variance, is performed if the data accords with normal distribution and the variance is of homogeneity. Otherwise, nonparameter test, known as rank sum test, is performed instead. The data are expressed as mean ± standard deviation, and P<0.05 is considered significant.
RESULTS
Comparison of the Therapeutic Effects
1. Effective rates in the two groups As shown in Table 2 , the total effective rate in Xuebijing treatment group was markedly higher than that of the control group (P<0.05).
2. Comparison of WBC, LDH and the peak body temperature As compared with the baseline, the WBC, LDH and peak body temperature showed a markedly reducing tendency in both the groups (Table 3) . WBC in both groups turned to normal on the 7th day. On the 14th day, the LDH level was significantly decreased in the Xuebijing treatment group, but no significant difference was found in the control group. The peak body temperature in the Xuebijing treatment group fell down to normal on the 3rd day, but it remained unchanged in patients of the control group on the 3rd day.
3. Comparison of the acute phase reactant levels ( Table  4) In patients of both groups, the serum CRP, 1 -AG levels showed an obviously decreasing tendency as the treatment went on. On the 3rd day, CRP and 1 -AG in the Xuebijing treatment group were significantly decreased, and lower than those in the control group (P<0.05). In the control group, the concentration of 1 -AT appeared to be ascending but consequently descending, whereas a notable decrease of 1 -AT was found in the Xuebijing treatment group (P<0.05). Generally speaking, as compared with the control group, the serum CRP, 1 -AG and 1 -AT levels in patients of the Xuebijing treatment group were decreased earlier and more obviously (P<0.05). 
Changes in the Levels of Cytokines
As shown in Table 5 the serum IL-6 level was reduced in both the two groups as the treatment went on. On the 3rd day, the IL-6 level in patients of the Xuebijing treatment group was obviously decreased as compared with the control group (P<0.05). The serum TNF-and IL-8 level were elevated the treatment went on; whereas no significant changes were observed in Xuebijing group, TNF-and IL-8 were markedly lower than the control group respectively on the 7th day and the 14th day. The leptin level showed no obvious change as compared with the baseline in both the groups. 
DISCUSSION
The pathogenesis of severe pneumonia is related with infection, toxin and the immunological factors, which consequently cause damage to the lung tissues. Among these factors, bacterial infection is the main cause for deterioration of pneumonia, but the use of antibiotics alone may not show good results. Some medical literature have reported that the combined use of herbal medicines for clearing the toxic heat, and expelling the sputum may help alleviate the stress reaction, accelerate the toxin elimination, and improve the respiratory function. Xuebijing Injection is a compound preparation of Chinese medicine with the efficacy of activating blood circulation to remove blood stasis, cooling the blood and clearing the toxic heat, which is composed of Chishao (Radix Paeoniae Rubra), Danggui (Radix Angelica Sinensis), Chuanxiong (Rhizoma Chuanxiong), Honghua (Flos Carthami), and Danshen (Radix Salviae Miltiorrhizae).
The present study shows that the use of antibiotics in combination with Xuebijing injection can notably decrease the serum LDH level, lower the daily peak body temperature, decline the acute phase reactants (CRP, 1 -AG and 1 -AT), and enhance the total effective rate in severe pneumonia patients. The secretion of TNF-, IL-6 and IL-8 in Xuebijing-treated patients was obviously suppressed as compared with the control group, but with no significant influence on the release of leptin. The main pathogenic bacteria in severe pneumonia are Gram negative, like Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli, etc. Lipopolysaccharide (LPS), a bioactive substance, exists in the adventitia of cell wall of the Gram negative bacterial, which is the main inducing substance for systemic inflammatory response syndrome (SIRS) and sepsis. 3, 4 Many researches have demonstrated that antibiotics can drive releasing of LPS while killing the bacteria, and LPS may consequently stimulate the macrophages to produce more inflammatory mediators, leading to deterioration of bacterial infection, or even SIRS and/or sepsis. 5, 6 Among the inflammatory factors, TNF-, IL-6 and IL-8 are the most influential, because they take part in the initial onset of SIRS, known as the preinflammatory mediators; Stimulate to produce more secondary inflammatory mediators, and induce the synthesis of acute phase reactants like CRP, 1 -AG and 1 -AT in the liver. This study showed that secretion of TNF-, IL-6 and IL-8 was suppressed on the 3rd, 7th and 14th day after Xuebijing treatment, indicating that Xuebijing Injection may extert anti-endotoxin effects by blocking the uncontrolled release of endogenic inflammatory mediators like TNF-, IL-6 and IL-8; as a result, the vacious cycle of inflammation onset is interrupted, the overactive inflammatory reactions are suppressed, the development of SIRS is blocked; meanwhile, the acute phase reactants are reduced, and the clinical symptoms are relieved, which conform to the results of many studies reported both at home and abroad. 7, 8 Leptin is a protein product encoded by fat gene. It has the effects on body weight regulatory circuit and feedback regulation of energy metabolics, it can also act as a cytokine to induce generation, differentiation and enhancement of hematopoietic cells, and provide monocytes with nutrition, enhance the generation and phagocytosis actions of mononuclear macrophages, stimulate the secretion of pre-inflammatory and antiinflammatory substances in monocytes, activate the vascular regeneration, and strengthen the body resistance. 9 Through observation of the influence of Xuebijing on leptin releasing, the study tries to explore whether the effect of Xuebijing is related with the enhancement or inhibition of leptin release. The results from the present study shows that Xuebijing has no significant influence on leptin release, possibly the secretion and regulation of leptin are influenced by lots of factors, among which the body weight and insulin level are the key factors.
To sum up, Xuebijing Injection can effectively regulate the inflammatory factors, alleviate the symptoms and various inflammation reactions in severe pneumonia, without obvious adverse side effects on the organ functions, and biochemical indexes.
